Extracellular Vesicle Antigen Detection via Immunofluorescence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting disease-related antigens on extracellular vesicles are time-consuming, costly, and require complex technologies, limiting their scalability and sensitivity for diagnostic applications.
Innovation Solution
A method involving the use of detection antibodies linked to detectable labels and capture antibodies immobilized on a substrate to specifically bind and immobilize extracellular vesicles, allowing for the detection of disease-specific antigens on their surface, such as CD9, CD63, and CD81, using a glass slide and fluorescent labeling for high-sensitivity immunofluorescence assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mass spectrometry or complicated electrical/optical sensor based on nano/micro-fabrication is used to detect disease-related antigens on extracellular vesicles, then measurement precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent uses extracellular vesicles as intermediary carriers that naturally transport disease-related biomarkers from tissues to peripheral circulation. By detecting antigens on these vesicles instead of free biomarkers, the method achieves higher specificity and sensitivity while using simpler immunoassay technology rather than complex mass spectrometry or nano-fabricated sensors.
Solution Approach 2:
The patent employs immunofluorescence labeling where fluorescent antibodies bind to antigens on extracellular vesicles, creating a detectable optical copy of the antigen presence. This allows visualization and quantification of disease markers using simple fluorescence microscopy or flow cytometry, replacing the need for complex mass spectrometry instrumentation.
2Measurement precision
If mass spectrometry or complicated electrical/optical sensor based on nano/micro-fabrication is used to detect disease-related antigens on extracellular vesicles, then measurement precision is improved, but cost increases
Solution Approach 1:
The patent uses disposable, commercially available fluorescent antibodies and standard laboratory reagents instead of expensive, specialized mass spectrometry consumables or custom-fabricated nano-sensors. The method can be performed with routine laboratory equipment, dramatically reducing per-test costs while maintaining high detection sensitivity through the specificity of antibody-antigen binding.
3Measurement precision
If conventional detection methods are used for extracellular vesicle antigens, then measurement precision is improved, but time consumption increases
Solution Approach 1:
The patent takes advantage of the fact that extracellular vesicles are already present in peripheral circulation and can be directly isolated from blood samples without complex tissue processing. The fluorescent antibodies are pre-prepared and can be applied directly to isolated vesicles, enabling rapid detection within hours rather than the extended processing times required by mass spectrometry sample preparation and analysis.
4Measurement precision
If conventional detection methods are used for extracellular vesicle antigens, then measurement precision is improved, but scalability decreases
Solution Approach 1:
The patent uses flow cytometry and immunofluorescence microscopy as universal detection platforms that can analyze thousands of extracellular vesicles in parallel. These methods are already standardized in clinical laboratories and can be easily scaled from research to clinical diagnostics without requiring specialized facilities or extensive method development, unlike mass spectrometry which requires highly specialized infrastructure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid, cost-effective, and highly sensitive detection of disease-specific antigens on extracellular vesicles, facilitating early disease diagnosis with high specificity and scalability, as demonstrated by its application in Alzheimer's disease diagnosis.
Implementation Method 1
a detection antibody specifically binds to a disease-specific antigen present on the surface of the circulating EV
Implementation Method 2
a capture antibody specifically binds to a surface antigen of the circulating EV, thus immobilizing the circulating EV on the substrate
Implementation Method 3
a detection antibody linked to a detectable label... detecting the detectable label on the circulating EV immobilized on the substrate
Data Source
AI summary
The present disclosure provides a method for diagnosis based on proteins present on the surface of circulating extracellular vesicles. The method comprises incubating a sample of the subject with a detection antibody linked to a detectable label, contacting the sample with a capture antibody immobilized on a substrate, and detecting the detectable label on the circulating EV immobilized on the substrate. Compared to the method currently known in the art, the method disclosed herein has the advantages of high sensitivity with low cost and rapid procedure, high specificity.